Predicated on the increasing abundance of electronic health records, we investigate the problem of inferring individualized treatment effects using observational data. Stemming from the potential outcomes model, we propose a novel multi-task learning framework in which factual and counterfactual outcomes are modeled as the outputs of a function in a vector-valued reproducing kernel Hilbert space (vvRKHS). We develop a nonparametric Bayesian method for learning the treatment effects using a multi-task Gaussian process (GP) with a linear coregionalization kernel as a prior over the vvRKHS. The Bayesian approach allows us to compute individualized measures of confidence in our estimates via pointwise credible intervals, which are crucial for realizing the full potential of precision medicine. The impact of selection bias is alleviated via a risk-based empirical Bayes method for adapting the multi-task GP prior, which jointly minimizes the empirical error in factual outcomes and the uncertainty in (unobserved) counterfactual outcomes. We conduct experiments on observational datasets for an interventional social program applied to premature infants, and a left ventricular assist device applied to cardiac patients wait-listed for a heart transplant. In both experiments, we show that our method significantly outperforms the state-of-the-art.
IBM Watson Health has formed a medical imaging collaborative with more than 15 leading healthcare organizations. The goal: To take on some of the most deadly diseases. The collaborative, which includes health systems, academic medical centers, ambulatory radiology providers and imaging technology companies, aims to help doctors address breast, lung, and other cancers; diabetes; eye health; brain disease; and heart disease and related conditions, such as stroke. Watson will mine insights from what IBM calls previously invisible unstructured imaging data and combine it with a broad variety of data from other sources, such as data from electronic health records, radiology and pathology reports, lab results, doctors' progress notes, medical journals, clinical care guidelines and published outcomes studies. As the work of the collaborative evolves, Watson's rationale and insights will evolve, informed by the latest combined thinking of the participating organizations.
Health care executives from IBM Watson and Athenahealth athn debated that question onstage at Fortune's inaugural Brainstorm Health conference Tuesday. In addition to partnering with Celgene celg to better track negative drug side effects, IBM ibm is applying its cognitive computing AI technology to recommend cancer treatment in rural areas in the U.S., India, and China, where there is a dearth of oncologists, said Deborah DiSanzo, general manager for IBM Watson Health. For example, IBM Watson could read a patient's electronic medical record, analyze imagery of the cancer, and even look at gene sequencing of the tumor to figure out the optimal treatment plan for a particular person, she said. "That is the promise of AI--not that we are going to replace people, not that we're going to replace doctors, but that we really augment the intelligence and help," DiSanzo said. Athenahealth CEO Jonathan Bush, however, disagreed.
Xu, Zhenxing, Chou, Jingyuan, Zhang, Xi Sheryl, Luo, Yuan, Isakova, Tamara, Adekkanattu, Prakash, Ancker, Jessica S., Jiang, Guoqian, Kiefer, Richard C., Pacheco, Jennifer A., Rasmussen, Luke V., Pathak, Jyotishman, Wang, Fei
Acute Kidney Injury (AKI) is a common clinical syndrome characterized by the rapid loss of kidney excretory function, which aggravates the clinical severity of other diseases in a large number of hospitalized patients. Accurate early prediction of AKI can enable in-time interventions and treatments. However, AKI is highly heterogeneous, thus identification of AKI sub-phenotypes can lead to an improved understanding of the disease pathophysiology and development of more targeted clinical interventions. This study used a memory network-based deep learning approach to discover predictive AKI sub-phenotypes using structured and unstructured electronic health record (EHR) data of patients before AKI diagnosis. We leveraged a real world critical care EHR corpus including 37,486 ICU stays. Our approach identified three distinct sub-phenotypes: sub-phenotype I is with an average age of 63.03$ \pm 17.25 $ years, and is characterized by mild loss of kidney excretory function (Serum Creatinne (SCr) $1.55\pm 0.34$ mg/dL, estimated Glomerular Filtration Rate Test (eGFR) $107.65\pm 54.98$ mL/min/1.73$m^2$). These patients are more likely to develop stage I AKI. Sub-phenotype II is with average age 66.81$ \pm 10.43 $ years, and was characterized by severe loss of kidney excretory function (SCr $1.96\pm 0.49$ mg/dL, eGFR $82.19\pm 55.92$ mL/min/1.73$m^2$). These patients are more likely to develop stage III AKI. Sub-phenotype III is with average age 65.07$ \pm 11.32 $ years, and was characterized moderate loss of kidney excretory function and thus more likely to develop stage II AKI (SCr $1.69\pm 0.32$ mg/dL, eGFR $93.97\pm 56.53$ mL/min/1.73$m^2$). Both SCr and eGFR are significantly different across the three sub-phenotypes with statistical testing plus postdoc analysis, and the conclusion still holds after age adjustment.
One of the ways AI is and will continue t be helpful in the field of healthcare is allowing medical professionals the ability to create treatment plans as well as discovering the best suited methods for helping their patients; instead of having to battle the tread-wheel of bureaucracy, nurses and physicians can focus on doing their actual jobs. Since we are in the age of big data, patient information is becoming valuable as tech giants, such as IBM and Google, are becoming more involved in acquiring this information; therefore, companies are using AI in the field known as patient data mining in a variety of ways. The AI research branch of the company recently launched a project known as Google Deepmind Health which focuses on mining medical records with the goal of providing faster and better health services; the project can go through hundreds of thousands of medical data within minutes. Also, Google's life sciences are working on a data-collecting initiative that aims to apply some of the same algorithms used to power Goggle's search button to analyze what it is that makes a person healthy. Included in this is experimenting with technologies that monitor diseases such as a digital contact lens that might detect levels of blood sugar.